{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028411","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.876726+00:00","generated_at":"2026-06-11T21:46:03.746961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials","bullets":["FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.","Net loss $18.0M for Q2 2023 (vs $18.3M prior year); cash $134.9M expected to fund into 2025.","PRECISION1 trial interim analysis on 40 patients with appropriate follow-up expected before end of 2023.","Phase 2 trials in endometrial cancer (nab-sirolimus + letrozole) and NETs to initiate in Q4 2023.","First patient dosed in Phase 1/2 KRAS G12C trial with adagrasib (Mirati collaboration)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028411","json":"https://secwatch.observer/filing/0001628280-23-028411.json","markdown":"https://secwatch.observer/filing/0001628280-23-028411.md","text":"https://secwatch.observer/filing/0001628280-23-028411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/0001628280-23-028411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/aadi-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:46:03.746961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0547b217504cffddaf77c120981e3f608877f41b","claim":"Whitehawk Therapeutics, Inc. reported the second quarter of 2023 results: revenue $6.2 million.","evidence_excerpt":"Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000162828023028411/0001628280-23-028411-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$6.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}